Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05607030 · ClinicalTrials.gov registry record · Phase 2
A Second Trial of the Abbreviated Protocol Two-Stage Exchange
A Phase 2 study of Prosthetic-joint Infection, sponsored by Osteal Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
- 19
- Study locations
NCT05607030: Completed Phase 2 study of Prosthetic-joint Infection, sponsored by Osteal Therapeutics.
NCT05607030 is a Phase 2 study of Prosthetic-joint Infection that has completed, run by Osteal Therapeutics. The registered enrollment target is 76 participants, below the 90-participant average among 9 other Prosthetic-joint Infection trials with a reported enrollment target (16% lower). The trial reports 19 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05607030, a Phase 2 study of Prosthetic-joint Infection, has completed, sponsored by Osteal Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
- 19
- Study locations
Study Summary
Apex-2 is a multi-site, parallel group, randomized trial. Patients will be randomly assigned in a 1:1 ratio to the Experimental Arm or the Control Arm. The objective of the study is to evaluate safety and determine efficacy of the VT-X7 system. Efficacy is evaluated as superiority of the Experimental Arm in a composite endpoint of Overall Success at 180 days, consisting of a revision prosthesis implanted at Stage 2, absence of periprosthetic joint infection (PJI), absence of continued antibiotic therapy for treatment or prophylaxis of PJI, absence of revision surgery and absence of mortality. Secondary objectives are to evaluate overall success at 365 days, overall safety of the VT-X7 procedure, quality of life (QoL), and patient survival. The exploratory objective is to compare Experimental and Control Arms in exploratory endpoints. Follow-up: Patients will be evaluated at 90-, 180-, and 365-day follow-up visits.
Primary Outcome
* Stage 2 revision prosthesis implanted and * Absence of PJI post-Stage 2 and * Absence of continued antibiotic therapy for treatment or prophylaxis of PJI and * Absence of revision surgery of the affected joint pre- and post-Stage 2 and * Absence of mortality.
Conditions Studied
Interventions
- COMBINATION_PRODUCT VT-X7 Treatment System
- PROCEDURE Two-stage exchange arthroplasty
- DRUG SOC Antibiotics
- DRUG Experimental Antibiotics
Study Locations (19)
Ohio
- University of Cincinnati - Cincinnati
- Bethesda North Hospital - TriHealth Hatton Research - Cincinnati
- Cleveland Clinic - Cleveland
- The Ohio State University Medical Center - Columbus
Florida
- Kennedy White Orthopaedic Center - Sarasota
- Cleveland Clinic Florida - Weston
Pennsylvania
- Rothman Orthopaedic Institute - Philadelphia
- University of Pittsburgh Medical Center - Pittsburgh
Arizona
- Banner - University Medical Center Phoenix - Phoenix
California
- Harbor UCLA Medical Center - Los Angeles
Michigan
- Covenant Medical Center - Saginaw
Minnesota
- Mayo Clinic - Rochester
Missouri
- University of Missouri - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2023-01-23 |
| Est. Completion | 2024-10-30 |
| Phase | Phase 2 |
What the finished NCT05607030 record still lists
NCT05607030 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 90-participant average among 9 other Prosthetic-joint Infection trials with a reported enrollment target (16% lower).
The record links to 1 condition, with Prosthetic-joint Infection appearing as the primary indexed condition, and to 4 interventions - of which VT-X7 Treatment System is the first listed.
NCT05607030 lists 19 locations in 14 states (Ohio, Florida, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT05607030 about?
NCT05607030 is a clinical study titled "A Second Trial of the Abbreviated Protocol Two-Stage Exchange". Apex-2 is a multi-site, parallel group, randomized trial. Patients will be randomly assigned in a 1:1 ratio to the Experimental Arm or the Control Arm. The objective of the study is to evaluate safety and determine efficacy of the VT-X7 system. Efficacy is evaluated as superiority of the Experiment...
What is the current status of trial NCT05607030?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2023-01-23. Estimated completion is 2024-10-30.
What conditions does trial NCT05607030 study?
This clinical trial studies the following conditions: Prosthetic-joint Infection.
What interventions are being tested in trial NCT05607030?
The interventions under investigation include: VT-X7 Treatment System (COMBINATION_PRODUCT), Two-stage exchange arthroplasty (PROCEDURE), SOC Antibiotics (DRUG), Experimental Antibiotics (DRUG).
Who is sponsoring clinical trial NCT05607030?
This trial is sponsored by Osteal Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05607030 being conducted?
This trial has 19 study locations across Arizona, California, Florida, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prosthetic-joint Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05607030's enrollment target sits among peer trials
76 5th of 9 higher than 5 of 9 other Prosthetic-joint Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prosthetic-joint Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty
RECRUITING · Phase 2
-
Safety and Efficacy in Patients Treated for Hip or Knee PJI With Vancomycin and Tobramycin Joint Irrigation
COMPLETED · Phase 2
-
The Effect of Peri-Operative Adjunctive Probiotics on Immunological Markers in Cases of Prosthetic Joint Infection of the Hip and Knee
RECRUITING · NA
-
Real-component Vs All-cement Articulating Spacers for Periprosthetic Knee Infection
RECRUITING · NA
-
Reduction of Bacterial Seeding in Total Shoulder Arthroplasty
RECRUITING · NA
-
SURGX Antimicrobial Gel Versus Povidone-iodine Skin Incision Prep in Total Shoulder Arthroplasty
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI